Jean Franchi Sells 353 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) CFO Jean Franchi sold 353 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $69.06, for a total value of $24,378.18. Following the transaction, the chief financial officer owned 70,990 shares in the company, valued at $4,902,569.40. This trade represents a 0.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Disc Medicine Trading Down 1.9%

NASDAQ IRON opened at $66.62 on Friday. The firm has a market capitalization of $2.51 billion, a PE ratio of -11.12 and a beta of 0.88. The stock’s 50 day moving average is $74.43 and its 200 day moving average is $75.51. Disc Medicine, Inc. has a twelve month low of $30.82 and a twelve month high of $99.50. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.62) EPS for the quarter, beating the consensus estimate of ($1.69) by $0.07. The firm had revenue of ($19.88) million for the quarter, compared to analysts’ expectations of $0.15 million. Research analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Disc Medicine

Institutional investors have recently made changes to their positions in the company. Invesco Ltd. increased its position in shares of Disc Medicine by 184.8% during the fourth quarter. Invesco Ltd. now owns 61,070 shares of the company’s stock valued at $4,850,000 after acquiring an additional 39,627 shares in the last quarter. KVP Capital Advisors LP purchased a new stake in Disc Medicine during the 4th quarter valued at $4,626,000. XTX Topco Ltd bought a new stake in shares of Disc Medicine in the 4th quarter worth $1,834,000. VARCOV Co. bought a new stake in shares of Disc Medicine in the 4th quarter worth $423,000. Finally, Vestal Point Capital LP raised its stake in shares of Disc Medicine by 47.0% in the fourth quarter. Vestal Point Capital LP now owns 735,000 shares of the company’s stock worth $58,366,000 after purchasing an additional 235,000 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

More Disc Medicine News

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Beat on quarterly results — Disc reported Q4 and full‑year 2025 results with EPS of ($1.62), beating consensus (($1.69)) and provided a business update; the small earnings beat is a short‑term positive signal for execution and guidance clarity. Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst target lowered but rating sustained — Truist cut its price target from $114 to $83 but kept a “buy” rating, signalling continued analyst confidence in the longer‑term thesis despite reduced near‑term expectations. Truist lowers price target to $83
• Neutral Sentiment: Insider sale by CFO — CFO Jean M. Franchi sold 353 shares at ~$69; the sale is small (0.49% reduction in her holdings) and appears routine rather than a clear signal of negative private information. CFO insider sale filing
• Neutral Sentiment: Short‑interest report is inconclusive — a MarketBeat entry shows anomalous/zero short interest data for February (days‑to‑cover 0.0), so there’s no clear short‑squeeze or elevated short pressure signal from this report.
• Negative Sentiment: Restructuring after FDA response — Disc’s board approved a restructuring following an FDA response, implying a regulatory/setback event that prompted corporate changes; this raises near‑term execution and timeline uncertainty for pipeline programs. Disc Medicine Implements Restructuring Following FDA Response
• Negative Sentiment: Investor litigation alert — Pomerantz LLP announced an investigation into Disc Medicine, which can increase legal risk, potential distraction, and perceived governance concerns among investors. Pomerantz investigates Disc Medicine

Analyst Upgrades and Downgrades

IRON has been the topic of several research reports. Morgan Stanley set a $75.00 price objective on shares of Disc Medicine in a research note on Tuesday, February 17th. TD Cowen reiterated a “buy” rating on shares of Disc Medicine in a report on Friday, December 19th. Wedbush cut their price target on Disc Medicine from $110.00 to $88.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 17th. Raymond James Financial reaffirmed a “market perform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Finally, BMO Capital Markets lowered their price objective on Disc Medicine from $120.00 to $100.00 and set an “outperform” rating for the company in a research note on Tuesday, February 17th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $102.00.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.